JP7821161B2 - Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 - Google Patents

Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子

Info

Publication number
JP7821161B2
JP7821161B2 JP2023510435A JP2023510435A JP7821161B2 JP 7821161 B2 JP7821161 B2 JP 7821161B2 JP 2023510435 A JP2023510435 A JP 2023510435A JP 2023510435 A JP2023510435 A JP 2023510435A JP 7821161 B2 JP7821161 B2 JP 7821161B2
Authority
JP
Japan
Prior art keywords
single variable
variable domain
bcma
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023510435A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022037528A5 (https=
JP2023539453A (ja
JP2023539453A5 (https=
Inventor
子 朋 甄
美 娟 謝
秀 貞 杜
毅 敏 馬
兵 張
同 杰 徐
喜 全 張
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2023539453A publication Critical patent/JP2023539453A/ja
Publication of JPWO2022037528A5 publication Critical patent/JPWO2022037528A5/ja
Publication of JP2023539453A5 publication Critical patent/JP2023539453A5/ja
Application granted granted Critical
Publication of JP7821161B2 publication Critical patent/JP7821161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023510435A 2020-08-20 2021-08-16 Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 Active JP7821161B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842501.X 2020-08-20
CN202010842501 2020-08-20
PCT/CN2021/112758 WO2022037528A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (4)

Publication Number Publication Date
JP2023539453A JP2023539453A (ja) 2023-09-14
JPWO2022037528A5 JPWO2022037528A5 (https=) 2024-08-26
JP2023539453A5 JP2023539453A5 (https=) 2024-08-26
JP7821161B2 true JP7821161B2 (ja) 2026-02-26

Family

ID=80323414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023510435A Active JP7821161B2 (ja) 2020-08-20 2021-08-16 Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子

Country Status (6)

Country Link
US (1) US20230265181A1 (https=)
EP (1) EP4201960A4 (https=)
JP (1) JP7821161B2 (https=)
KR (1) KR20230045095A (https=)
CN (1) CN115698077A (https=)
WO (1) WO2022037528A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体
WO2025098446A1 (zh) * 2023-11-07 2025-05-15 赛斯尔擎生物技术（上海）有限公司 抗bcma单域抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942709A (zh) 2019-04-22 2019-06-28 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN109942708A (zh) 2019-03-28 2019-06-28 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2406284B9 (en) * 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
IL271194B2 (en) * 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
AU2019214183B2 (en) * 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942708A (zh) 2019-03-28 2019-06-28 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用
CN109942709A (zh) 2019-04-22 2019-06-28 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用

Also Published As

Publication number Publication date
US20230265181A1 (en) 2023-08-24
EP4201960A1 (en) 2023-06-28
EP4201960A4 (en) 2024-09-04
JP2023539453A (ja) 2023-09-14
CN115698077A (zh) 2023-02-03
KR20230045095A (ko) 2023-04-04
WO2022037528A1 (zh) 2022-02-24

Similar Documents

Publication Publication Date Title
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
CN115052895B (zh) 抗SIRPα抗体及其用途
CA3089260A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN113412281A (zh) Btn3a结合蛋白及其用途
KR20200063147A (ko) Pdl1 표적화 항체 및 이의 사용 방법
CN109721656B (zh) 靶向rankl的治疗性抗体
US20220098326A1 (en) Method for generating avid-binding multispecific antibodies
CN114790242A (zh) 一种结合人pd-l1的抗体
KR20250152073A (ko) 항체, 항원 결합 단편 및 사용 방법
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP7821161B2 (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
JP2023519620A (ja) Ｃｄ４７に結合する抗原結合ポリペプチド及び用途
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP7821159B2 (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
US12612635B2 (en) BCMA-binding single variable structural domain and antigen-binding molecule
JP7851924B2 (ja) 抗ｔｒｏｐ－２抗体、その抗原結合断片又はその変異体、及びそれらの医学的使用
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
JP7773238B2 (ja) Ｐｄ－ｌ１に対する単一ドメイン抗体及びその用途
JP2010533732A (ja) プロテアーゼ活性化受容体−１（ｐａｒ１）のアンタゴニスト抗体
JP2026504831A (ja) ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及びそれらの医薬的使用
TW202432593A (zh) 抗體、其抗原結合片段及其藥物用途
CN121895452A (zh) 抗激活素2型受体的抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821161

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150